Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $208,449.12 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 5,808 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $208,449.12. Following the transaction, the chief executive officer now directly owns 476,046 shares in the company, valued at approximately $17,085,290.94. This represents a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB opened at $36.69 on Friday. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.77. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of -13.25 and a beta of 1.07. The stock has a 50 day moving average price of $32.61 and a 200 day moving average price of $28.69.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Thursday, March 27th. Bank of America reissued a “neutral” rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. JPMorgan Chase & Co. upped their price objective on Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, March 13th. Finally, Scotiabank initiated coverage on Zai Lab in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab in the 4th quarter valued at about $29,000. Public Employees Retirement System of Ohio raised its stake in Zai Lab by 20.8% in the fourth quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after buying an additional 3,179 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after buying an additional 1,200 shares during the period. Woodline Partners LP boosted its position in Zai Lab by 9.4% during the 4th quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock valued at $46,089,000 after acquiring an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in shares of Zai Lab in the 4th quarter valued at $7,857,000. 41.65% of the stock is currently owned by institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.